What is PT-141?
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide that acts as a non-selective agonist of melanocortin receptors, with particular affinity for the MC4R (melanocortin-4 receptor) in the central nervous system. Developed originally from the tanning peptide Melanotan II, PT-141 was found to have potent effects on sexual arousal independent of its melanogenic properties. The compound received FDA approval in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women [4].
The mechanism of PT-141 is fundamentally different from phosphodiesterase-5 inhibitors (sildenafil, tadalafil) that work through vascular pathways. PT-141 acts centrally, activating melanocortin pathways in the hypothalamus that modulate sexual desire and arousal through dopaminergic and oxytocinergic signaling. This means PT-141 targets the desire component of sexual function rather than the mechanical/vascular component, making it effective in contexts where PDE5 inhibitors fail, including psychogenic erectile dysfunction and female sexual dysfunction.
In clinical trials, PT-141 demonstrated statistically significant improvements in sexual desire, with approximately 25% of treated women reporting meaningful improvement in desire versus 17% with placebo [4]. In male studies (prior to the female-focused FDA approval), PT-141 induced erections in 8 of 10 men with erectile dysfunction, including subjects who had not responded to sildenafil [3]. The compound typically takes effect within 45–60 minutes and has a duration of action of 6–12 hours.
Mechanism of Action
PT-141 operates through a unique central nervous system pathway distinct from all other sexual function compounds:
Melanocortin-4 Receptor (MC4R) Activation
PT-141 binds and activates the melanocortin-4 receptor in the hypothalamus, specifically in the paraventricular nucleus (PVN) and medial preoptic area (MPOA). These brain regions are centrally involved in sexual behavior, arousal, and desire. MC4R activation triggers downstream signaling cascades that modulate sexual function [2].
Dopaminergic Signaling
MC4R activation in the hypothalamus stimulates dopamine release in brain regions associated with reward, motivation, and sexual arousal. This dopaminergic component is believed to be the primary driver of PT-141's pro-sexual effects, as dopamine is a key neurotransmitter in the neural circuitry of desire and arousal.
Oxytocinergic Pathway
PT-141 also stimulates oxytocin release from the PVN. Oxytocin has well-established roles in sexual function, pair bonding, and physiological arousal responses. The oxytocinergic component may contribute to both the subjective experience of desire and the peripheral physiological responses (genital blood flow, lubrication) observed with PT-141 administration.
Central vs. Peripheral Mechanism
Unlike PDE5 inhibitors that act on vascular smooth muscle, PT-141 acts on the brain. This fundamental difference explains why PT-141 can address desire dysfunction (HSDD), not just arousal mechanics. It also explains why PT-141 is effective in individuals who fail PDE5 inhibitor therapy — the target pathways do not overlap [3].
Dosing Protocol
PT-141 is used on an as-needed basis, not as a daily medication. Frequency limitations help prevent melanocortin receptor desensitization.
| Protocol | Dose | Timing | Notes |
|---|---|---|---|
| FDA-approved (female) | 1.75 mg SubQ | 45 min before anticipated activity | Approved Vyleesi dose |
| Research (male) | 1–2 mg SubQ | 45–60 min before | Based on clinical study data |
| Frequency limit | As above | Max once per 24 hours | No more than 8 doses per month recommended |
- Administer at least 45 minutes before anticipated activity. Effects typically begin within 45–60 minutes.
- Duration of action is 6–12 hours. Some individuals report effects lasting up to 24 hours.
- Do not exceed 8 doses per month. Excessive use may lead to melanocortin receptor desensitization.
- Lower starting doses (1 mg) may help assess individual tolerance, particularly regarding nausea.
- PT-141 can be taken with or without food, though nausea is more common on an empty stomach.
Reconstitution Guide
Reconstitute lyophilized PT-141 with bacteriostatic water. PT-141 is a cyclic peptide with good stability characteristics.
- Remove the plastic cap from the PT-141 vial and wipe the rubber stopper with an alcohol swab. Allow to dry.
- Draw
2 mLof bacteriostatic water into a sterile syringe. For a 10 mg vial, this yields a concentration of5 mg/mL. - Insert the needle through the rubber stopper at a slight angle. Inject the water slowly against the inner wall of the vial — do not spray directly onto the peptide powder.
- Allow the vial to sit for 1–2 minutes. Gently roll the vial between your palms if needed. Do not shake or vortex.
- The solution should be completely clear and colorless. Discard if you observe any cloudiness, particulate matter, or discoloration.
10 mg vial + 2 mL BAC water: Concentration = 5 mg/mL
1.75 mg dose = 35 units (0.35 mL) on a 100-unit insulin syringe
2 mg dose = 40 units (0.40 mL) on a 100-unit insulin syringe
Doses per vial: ~5 doses at 2 mg, or ~5 doses at 1.75 mg
- 1–2 vials PT-141 (10 mg each) — provides 5–10 doses per vial at standard dosing
- 1 vial bacteriostatic water (30 mL)
- Insulin syringes (29–31 gauge, 100-unit)
- Alcohol prep pads
Injection Technique
PT-141 is administered via subcutaneous (SubQ) injection. The injection site does not affect efficacy.
- Clean the injection site with an alcohol swab and allow it to air dry completely (approximately 30 seconds). Common sites: lower abdomen (2 inches from the navel), upper thigh, or upper arm.
- Draw the dose. Insert the needle into the vial through the rubber stopper. Invert the vial and draw the calculated number of units slowly. Tap the syringe to move any air bubbles to the top, then push them out gently.
- Pinch the skin at the injection site to create a fold of subcutaneous tissue. Insert the needle at a 45-degree angle in a quick, smooth motion. Release the skin fold.
- Inject slowly. Depress the plunger steadily over 5–10 seconds. Withdraw the needle at the same angle it was inserted. Apply gentle pressure with a clean swab if needed.
Given the as-needed dosing pattern (max 8x per month), injection site rotation is less critical than with daily-use peptides but should still be practiced. Alternate between left and right abdomen, or rotate between abdomen and thigh.
Storage & Stability
PT-141 is a cyclic peptide with good stability characteristics. The cyclic structure confers resistance to enzymatic degradation.
- Keep vials upright and away from direct light.
- If condensation forms on a cold vial, allow it to reach room temperature before opening to prevent moisture contamination.
- Never re-freeze a reconstituted vial. Discard if left at room temperature for more than 4 hours.
- Label reconstituted vials with the date to track the 30-day use window.
Side Effects & Considerations
PT-141 has a well-characterized safety profile from its FDA approval process. Nausea is the most commonly reported side effect.
Commonly Reported
- Nausea — the most common side effect, reported in ~40% of clinical trial participants. Usually resolves within 2 hours. Most pronounced on the first dose and diminishes with subsequent use.
- Flushing and facial warmth — from melanocortin receptor activation. Generally mild and transient.
- Headache — reported in ~11% of subjects in clinical trials.
- Injection site reactions — bruising, redness at the injection area.
Serious Considerations
- Transient blood pressure elevation — small increases (2–4 mmHg) observed. Clinically insignificant in healthy individuals but potentially relevant in uncontrolled hypertension.
- Skin darkening or hyperpigmentation — with repeated use, due to melanocortin-1 receptor activation. More pronounced with frequent dosing.
- Contraindicated in uncontrolled hypertension and significant cardiovascular disease.
- Limit to 8 doses per month to prevent melanocortin receptor desensitization and minimize cumulative side effects.
PT-141 (bremelanotide) is FDA-approved under the brand name Vyleesi for treatment of HSDD in premenopausal women. Research-grade lyophilized PT-141 is classified separately. All information presented here reflects published clinical research. Consult a licensed healthcare provider before use.
PT-141 is available in 10 mg vials from Heritage Labs USA, a U.S.-based research peptide supplier with batch-level purity verification.
- Third-party purity testing (HPLC & MS)
- U.S.-based fulfillment
- Published COAs per lot
Literature & Citations
- Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325-337. PubMed
- Diamond LE, Earle DC, Heiman JR, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638. PubMed
- Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-142. PubMed
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PubMed
- Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. J Sex Med. 2008;5(5):1135-1148. PubMed
- Molinoff PB, Shadiack AM, Earle D, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. PubMed